Structural optimization of Zn(II)-activated magnetic resonance imaging probes.

We report the structural optimization and mechanistic investigation of a series of bioactivated magnetic resonance imaging contrast agents that transform from low relaxivity to high relaxivity in the presence of Zn(II). The change in relaxivity results from a structural transformation of the complex that alters the coordination environment about the Gd(III) center. Here, we have performed a series of systematic modifications to determine the structure that provides the optimal change in relaxivity in response to the presence of Zn(II). Relaxivity measurements in the presence and absence of Zn(II) were used in conjunction with measurements regarding water access (namely, number of water molecules bound) to the Gd(III) center and temperature-dependent (13)C NMR spectroscopy to determine how the coordination environment about the Gd(III) center is affected by the distance between the Zn(II)-binding domain and the Gd(III) chelate, the number of functional groups on the Zn(II)-binding domain, and the presence of Zn(II). The results of this study provide valuable insight into the design principles for future bioactivated magnetic resonance probes.

[1]  Claudio Luchinat,et al.  Mechanistic studies of a calcium-dependent MRI contrast agent. , 2002, Inorganic chemistry.

[2]  Ralph Weissleder,et al.  Molecular imaging in the clinical arena. , 2005, JAMA.

[3]  T. Meade,et al.  A Gadolinium Chelate for Detection of β-Glucuronidase: A Self-Immolative Approach , 2005 .

[4]  Scott E. Fraser,et al.  A SMART MAGNETIC RESONANCE IMAGING AGENT THAT REPORTS ON SPECIFIC ENZYMATIC ACTIVITY , 1997 .

[5]  T. Meade,et al.  The synthesis and in vitro testing of a zinc-activated MRI contrast agent , 2007, Proceedings of the National Academy of Sciences.

[6]  Yong Y. He,et al.  The Role of Zinc in Selective Neuronal Death After Transient Global Cerebral Ischemia , 1996, Science.

[7]  Thomas J Meade,et al.  Mechanisms of ZnII-activated magnetic resonance imaging agents. , 2008, Inorganic chemistry.

[8]  M. Pagel,et al.  Enzyme-responsive PARACEST MRI contrast agents: a new biomedical imaging approach for studies of the proteasome. , 2007, Contrast Media & Molecular Imaging.

[9]  Thomas J Meade,et al.  Magnetic resonance contrast agents for medical and molecular imaging. , 2004, Metal ions in biological systems.

[10]  Thomas J Meade,et al.  Bioresponsive, cell-penetrating, and multimeric MR contrast agents. , 2009, Accounts of chemical research.

[11]  S. Quici,et al.  Visible and near-infrared intense luminescence from water-soluble lanthanide [Tb(III), Eu(III), Sm(III), Dy(III), Pr(III), Ho(III), Yb(III), Nd(III), Er(III)] complexes. , 2005, Inorganic chemistry.

[12]  M. Botta,et al.  DEPENDENCE OF THE RELAXIVITY AND LUMINESCENCE OF GADOLINIUM AND EUROPIUM AMINO-ACID COMPLEXES ON HYDROGENCARBONATE AND PH , 1999 .

[13]  A Dean Sherry,et al.  A new gadolinium-based MRI zinc sensor. , 2009, Journal of the American Chemical Society.

[14]  Ick Chan Kwon,et al.  Activatable imaging probes with amplified fluorescent signals. , 2008, Chemical communications.

[15]  S. Baker,et al.  A copper-activated magnetic resonance imaging contrast agent with improved turn-on relaxivity response and anion compatibility. , 2010, Dalton transactions.

[16]  A. Sherry,et al.  Towards the rational design of magnetic resonance imaging contrast agents: isolation of the two coordination isomers of lanthanide DOTA-type complexes. , 2003, Angewandte Chemie.

[17]  K. Gee,et al.  Measuring zinc in living cells. A new generation of sensitive and selective fluorescent probes. , 2002, Cell calcium.

[18]  Ralph Weissleder,et al.  Near-infrared fluorescence: application to in vivo molecular imaging. , 2010, Current opinion in chemical biology.

[19]  A. Sherry,et al.  Effect of the regiochemistry of butyl amide substituents on the solution-state structures of lanthanide(III) DOTA-tetraamide complexes. , 2009, Inorganic chemistry.

[20]  Peter Caravan,et al.  Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. , 2006, Chemical Society reviews.

[21]  Mark D Pagel,et al.  Imaging in Vivo Extracellular pH with a Single Paramagnetic Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Contrast Agent , 2012, Molecular imaging.

[22]  S Aime,et al.  pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. , 2001, Journal of the American Chemical Society.

[23]  Scott E. Fraser,et al.  In vivo visualization of gene expression using magnetic resonance imaging , 2000, Nature Biotechnology.

[24]  J. Lindner.  Contrast ultrasound molecular imaging: harnessing the power of bubbles. , 2009, Cardiovascular research.

[25]  N. Oku,et al.  Zinc movement in the brain under kainate-induced seizures , 2003, Epilepsy Research.

[26]  Christopher J. Chang,et al.  A smart magnetic resonance contrast agent for selective copper sensing. , 2006, Journal of the American Chemical Society.

[27]  T. Meade,et al.  A modular system for the synthesis of multiplexed magnetic resonance probes. , 2011, Journal of the American Chemical Society.

[28]  A. Sherry,et al.  The population of SAP and TSAP isomers in cyclen-based lanthanide(III) chelates is substantially affected by solvent. , 2010, Inorganic chemistry.

[29]  Claudio Luchinat,et al.  Mechanistic Investigation of β-Galactosidase-Activated MR Contrast Agents , 2008 .

[30]  J. H. Viles,et al.  Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zinc and iron in Alzheimer's, Parkinson's and prion diseases , 2012 .

[31]  Byunghee Yoo,et al.  A PARACEST MRI contrast agent to detect enzyme activity. , 2006, Journal of the American Chemical Society.

[32]  O. Bagasra,et al.  hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer , 2005, Molecular Cancer.

[33]  Thomas J Meade,et al.  Molecular imaging of in vivo gene expression. , 2010, Future medicinal chemistry.

[34]  R. Weissleder,et al.  Optical-based molecular imaging: contrast agents and potential medical applications , 2003, European Radiology.

[35]  M. Botta,et al.  Relaxometric and luminescence behaviour of triaquahexaazamacrocyclic complexes, the gadolinium complex displaying a high relaxivity with a pronounced pH dependence , 1998 .

[36]  Paul M Matthews,et al.  Non-invasive imaging in experimental medicine for drug development. , 2011, Current opinion in pharmacology.

[37]  T. Meade,et al.  Receptor mediated uptake of a radiolabeled contrast agent sensitive to beta-galactosidase activity. , 2003, Nuclear Medicine and Biology.

[38]  A. Sherry,et al.  Solution dynamics and stability of lanthanide(III) (S)-2-(p-nitrobenzyl)DOTA complexes. , 2004, Inorganic chemistry.

[39]  R. Weissleder,et al.  Molecular imaging in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[40]  Anna Moore,et al.  A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. , 2010, Cancer research.

[41]  Dorothee P. Auer,et al.  Quantitative imaging biomarkers in neuro-oncology , 2009, Nature Reviews Clinical Oncology.

[42]  Francisco E. Robles,et al.  Molecular imaging true-colour spectroscopic optical coherence tomography. , 2011, Nature photonics.

[43]  M. Schabel,et al.  Towards the rational design of MRI contrast agents: δ-substitution of lanthanide(III) NB-DOTA-tetraamide chelates influences but does not control coordination geometry. , 2011, Chemistry.

[44]  T. Meade,et al.  Preparation of magnetic resonance contrast agents activated by β-galactosidase , 2008, Nature Protocols.

[45]  J. A. Hendricks,et al.  Corrigendum: Synthesis of [18F]BODIPY: Bifunctional Reporter for Hybrid Optical/Positron Emission Tomography Imaging , 2012 .

[46]  K. W. Kim,et al.  Zinc as a paracrine effector in pancreatic islet cell death. , 2000, Diabetes.

[47]  C. Contag,et al.  Molecular Imaging of Inflammation and Carcinogenesis , 2011, Cancer Prevention Research.

[48]  M. Farooq,et al.  Clinical Significance of Serum Zinc Levels in Cerebral Ischemia , 2011, Stroke research and treatment.

[49]  A. Bush,et al.  Zinc in the physiology and pathology of the CNS , 2009, Nature Reviews Neuroscience.

[50]  Paul M. Matthews,et al.  Positron emission tomography molecular imaging for drug development. , 2012, British journal of clinical pharmacology.

[51]  A Dean Sherry,et al.  Noninvasive MRI of β-cell function using a Zn2+-responsive contrast agent , 2011, Proceedings of the National Academy of Sciences.

[52]  A. Sherry,et al.  A responsive europium(III) chelate that provides a direct readout of pH by MRI. , 2010, Journal of the American Chemical Society.

[53]  Ashley I Bush,et al.  Metals in Alzheimer's and Parkinson's diseases. , 2008, Current opinion in chemical biology.

[54]  M. Tweedle,et al.  Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.

[55]  S. Fraser,et al.  A Calcium-Sensitive Magnetic Resonance Imaging Contrast Agent , 1999 .

[56]  T. Meade,et al.  Reporter protein-targeted probes for magnetic resonance imaging. , 2011, Journal of the American Chemical Society.

[57]  Katherine W Ferrara,et al.  Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. , 2009, Accounts of chemical research.